XARELTO®: Dosing for stroke risk reduction in nonvalvular atrial fibrillation (NVAF)

ONCE-DAILY DOSING* WITH 24-HOUR STROKE RISK REDUCTION1,2

*Taken with evening meal.

20 mg

Once daily with the evening meal in patients with CrCl >50 mL/min

15 mg

MODERATE TO SEVERE RENAL IMPAIRMENT DOSE


Once daily with the evening meal in patients with CrCl ≤50 mL/min

Renal Dosing Considerations

  • Adjust XARELTO® dose based on renal function
  • Periodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly
  • Consider dose adjustment or discontinuation of XARELTO® in patients who develop acute renal failure while taking XARELTO®
  • See section 8.6 of the Prescribing Information for additional information

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

Patients were considered at an increased risk for stroke if they had a higher CHADS2 score (range 1-6). Patients in ROCKET AF had a mean CHADS2 score of 3.5.

NVAF = nonvalvular atrial fibrillation; CrCl = creatinine clearance.